Clinical Trials

NCT Number: NCT04839991 Phase: Trial Summary: FIH, Phase 1, open-label, multi centre study of CB307, a trispecific Humabody® T-cell enhancer, in patients with advanced and/or metastatic PSMA+ solid tumours to assess safety and tolerability to de – clinicaltrials.gov for more information and location Clinicaltrials.gov Trial Sponsor(s): Crescendo Biologics Ltd. Acronym: POTENTIA

NCT Number: NCT05467176 Phase: Trial Summary: This is a multi-center, prospective, observational study of patients being treated with ORGOVYX. The goal of this study is to generate real-world evidence about the safety and effectiveness of ORGOVYX – clinicaltrials.gov for more information and location Clinicaltrials.gov Trial Sponsor(s): Myovant Sciences GmbH Acronym: OPTYX

NCT Number: NCT05568550 Phase: Trial Summary: This trial will evaluate whether the immune-sensitizing effects of immunotherapy (Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the effects of immunotherapy in – clinicaltrials.gov for more information and location Clinicaltrials.gov Trial Sponsor(s): Zin W Myint Acronym:

NCT Number: NCT04221542 Patient Summary Phase: PHASE1 Trial Summary: Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).  – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Amgen Acronym:

NCT Number: NCT04995198 Patient Summary Phase: Trial Summary: PROMISE aims to create a comprehensive nationwide registry of prostate cancer patients with germline pathogenic variants by prospectively screening approximately 5,000 subjects with a confirmed prostate cancer diagnosis, either through tissue biopsy, PSA greater than 100 ng/dL and/or radiographic evidence of disease and receiving systemic therapy for […]

NCT Number: NCT04933084 Phase: NA Trial Summary: This is a triple-armed, randomized, controlled, non-blinded trial to study the effect of preoperative patient education in conjunction with a limited opioid peri-operative analgesia program on post-op – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Benaroya Research Institute Acronym:

NCT Number: NCT05220501 Phase: NA Trial Summary: OPTIMUM is a study designed to compare the ability of ultra-high resolution transrectal micro-ultrasound (microUS) and multiparametric MRI (mpMRI)/US fusion to guide prostate biopsy. – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Sunnybrook Health Sciences Centre Acronym: OPTIMUM

NCT Number: NCT05155501 Phase: NA Trial Summary: This is a prospective, randomized controlled trial to compare cancer control and health-related quality of life following pelvic fascia-sparing radical prostatectomy versus standard radical prostatect – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Weill Medical College of Cornell University Acronym: PARTIAL

NCT Number: NCT05710380 Phase: NA Trial Summary: Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Chicago Acronym:

NCT Number: NCT05805371 Phase: PHASE1 Trial Summary: This phase Ib trial tests the safety, side effects, and best dose of autologous anti-prostate stem cell antigen (PSCA)-chimeric antigen receptor (CAR)-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes (PSC – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): City of Hope Medical Center Acronym: